5-MAPBT, also known as 5-(2-(methylamino)propyl)-1-benzothiophene, is a possible entactogen of the phenethylamine, amphetamine, and benzothiophene families. It is closely related to 5-MAPB, but with the oxygen atom replaced by sulfur, changing the core ring structure to benzothiophene rather than benzofuran.
The drug acts as a potent monoamine releasing agent, including of serotonin and dopamine, and as a potent serotonin 5-HT<sub>1B</sub> receptor agonist and serotonin 5-HT<sub>2B</sub> receptor antagonist. It is also a monoamine oxidase A (MAO-A) inhibitor, with an of 765nM.
It produces anxiolytic-like and antiobsessional-like effects in the marble burying test in rodents. However, benzothiophenes like 5-MAPBT, despite their induction of dopamine release, are said to lack hyperlocomotion or stimulant-like effects in rodents.
5-MAPBT has been studied and patented by Matthew J. Baggott at Tactogen. The drug has also been patented by Mydecine and given the developmental code name MY400.